TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05502666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ¡Salud! Por la Vida
Description: Lay health worker (LHW) delivered educational intervention for colorectal cancer screening (CRCS). The intervention consisted in having the participant complete a tailored interactive multimedia intervention (TIMI). TIMI consisted of a series of educational videos that addressed common barriers to colorectal cancer screening as well as provided information about colorectal cancer (CRC) and CRCS tests. Participants were able to tailor the TIMI for sex (male/female) and CRC family history. After TIMI completion, the LHW provided participant with a copy of the SPLV newsletter and printed infographics on CRC, CRCS, and an action plan tailored by type of CRCS (FOBT/FIT or colonoscopy). The Intervention Group subject participation took approx. up to 2 hours and Control Group up to 1 hour (half hour for each: baseline and follow-up interview). Follow-up data was collected 6 months post education session (intervention group) or post-baseline survey (control group).
Study: NCT00300677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily
Study: NCT03917069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic Combinations
Description: nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d
Study: NCT03684304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Description: The abdominal binder is an elastic abdominal compression / support device that will be placed on the patient after surgery has been completed.
Study: NCT03732365

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ultrasonic Drug Delivery
Description: A maximum dose of 2 grams cefazolin in a solution of 1 gram/100 mL sterile saline will be injected into the affected area, followed by a 3-minute application of external ultrasound delivered at an acoustic intensity equal to 3 watts/square centimeter of surface area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Antibiotic Treatment
Description: Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
Study: NCT03458702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YogaFit
Description: For YogaFit Vinyasa Flow (referred to as YogaFit in this manuscript)\], participants followed, via digital versatile disc, a standardized YogaFit format choreographed by an American Council of Exercise Certified and Registered Yoga Teacher (RYT). YogaFit was performed in the same laboratory setting and lasted 30 min. YogaFit is a westernized version of yoga that does not use Sanskrit terms (Shaw 2009). Breath was an integral part of every movement with specific breath rates for each phase of the session. The objective was to move the body with intention and purpose and be present in the body.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YogaFit
Description: For YogaFit Vinyasa Flow (referred to as YogaFit in this manuscript)\], participants followed, via digital versatile disc, a standardized YogaFit format choreographed by an American Council of Exercise Certified and Registered Yoga Teacher (RYT). YogaFit was performed in the same laboratory setting and lasted 30 min. YogaFit is a westernized version of yoga that does not use Sanskrit terms (Shaw 2009). Breath was an integral part of every movement with specific breath rates for each phase of the session. The objective was to move the body with intention and purpose and be present in the body.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quiet Rest
Description: Participants completed 30 min of quiet rest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quiet Rest
Description: Participants completed 30 min of quiet rest
Study: NCT03677479

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: socket preservation procedure
Description: socket preservation of post extraction site using bone xenografts

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket preservation procedure
Description: socket preservation of post extraction site using bone xenografts
Study: NCT04235569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Sodium 5 MG
Description: warfarin sodium 5mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Sodium 3 MG
Description: warfarin sodium 3mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Sodium 100 MG/ML Prefilled Syringe
Description: Clexane® Syringes 2,000 IU (20 mg)/0.2 ml solution for injection in pre-filled syringes.~Clexane® Syringes 4,000 IU (40 mg)/0.4 ml solution for injection in pre-filled syringes.~Clexane® Syringes 6,000 IU (60 mg)/0.6 ml solution for injection in pre-filled syringes.~Clexane® Syringes 8,000 IU (80 mg)/0.8 ml solution for injection in pre-filled syringes.~Dose was determined individually for each patient as 1mg/kg every 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Sodium 100 MG/ML Prefilled Syringe
Description: Clexane® Syringes 2,000 IU (20 mg)/0.2 ml solution for injection in pre-filled syringes.~Clexane® Syringes 4,000 IU (40 mg)/0.4 ml solution for injection in pre-filled syringes.~Clexane® Syringes 6,000 IU (60 mg)/0.6 ml solution for injection in pre-filled syringes.~Clexane® Syringes 8,000 IU (80 mg)/0.8 ml solution for injection in pre-filled syringes.~Dose was determined individually for each patient as 1mg/kg every 12 hours.
Study: NCT02086201

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy
Description: PST is a behavioral intervention for depression that is delivered by trained therapists over a 9 week period. It consists of a process to help patients understand and then solve the problems in their lives they feel is contributing to their depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage
Description: Engage is a weekly behavioral intervention that is delivered over a 9 week period of time by trained therapists. The focus of Engage is to help patient reconnect with activities that they have lost interest in pursuing due to depression.
Study: NCT03078738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMT-28
Description: OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMT-28
Description: OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMT-28
Description: OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMT-28
Description: OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Microcrystalline cellulose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Microcrystalline cellulose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Microcrystalline cellulose
Study: NCT04364061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise
Description: Participant completed a moderate intensity continuous cycling exercise (MICE) during 35 min at 60-65% thPHRmax

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (1)
Description: Participant completed a high-intensity interval cycling exercise (HIIE 1) during 20min with 60 cycles of speeding up for 8s and pedaling slowly for 12s at 80-90% thPHRmax

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (2)
Description: Participant completed a high-intensity interval cycling exercise (HIIE 2) during 20min with 10 x 1-min bouts at 80-90% thPHRmax, separated by 1-min recovery bouts
Study: NCT01547312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Interferon
Description: Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Interferon
Description: Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Samples from FNA
Description: Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Samples from FNA
Description: Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Samples from FNA
Description: Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Samples from CNB
Description: Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Samples from CNB
Description: Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Samples from CNB
Description: Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
Study: NCT03642210

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52 mg intrauterine system
Description: Levonorgestrel 52 mg intrauterine system
Study: NCT00150072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Study: NCT00946426

Intervention type: OTHER
Intervention: Clamp
Description: Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
Study: NCT01370226

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBI
Description: The multimedia, interactive Computer Brief Intervention (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The 30-minute interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TBI
Description: Participants receive a 30-minute intervention session with a Master's-level clinician. The interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant.
Study: NCT03104114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmacist-intervention
Description: A clinical pharmacist provides patients with motivational counseling regarding their cancer treatments. Patients will be asked to complete three different surveys throughout the study; surveys focus on social support systems and both provider- and pharmacist-patient relationships

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Historical control
Description: Patients that did not receive in-person motivational counseling support from a clinical pharmacist prior and during treatment
Study: NCT00507442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE (bortezomib)
Description: bortezomib 1.3 mg/m\^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE (bortezomib)
Description: bortezomib 1.3 mg/m\^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE (bortezomib)
Description: bortezomib 1.3 mg/m\^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE (bortezomib)
Description: bortezomib 1.3 mg/m\^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 500 mg/m\^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
Study: NCT01547312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Samples
Description: Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
Study: NCT00507442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 500 mg/m\^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 500 mg/m\^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid (lenalidomide)
Description: lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)~lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid (lenalidomide)
Description: lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)~lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)
Study: NCT02044744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity referral
Description: Provision of a primary care referral to at least one community-based physical activity program that is a good match for the participant's needs and preferences and patient follow-up on enrollment.
Study: NCT00385996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva (Erlotinib)
Description: Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
Study: NCT00695396

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching volume 2 mLfor 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: 40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching volume 1 mL for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: 80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
Study: NCT02161614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04681716

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ELDOA
Description: For Spinal Segment L4-L5 and L5-S1 proper ELDOA position was instructed to the experiment group patients.ELDOA stands for Elongation Longitudinaux Avec Decoaption Osteo Articulaire, or LOADS (Longitudinal Osteo-articular De-coaptation Stretching). ... They can be described as fascial stretch that localizes tension at the level of a specific spinal segmental.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONVENTIONAL PHYSIOTHERAPY
Description: Transcutaneous Electrical Nerve Stimulation (TENS):~120Z dual channel TENS unit made in Japan was used in the research. Electrodes of TENS were placed on lumbar region and TENS was given for 15 minutes on Constant mode. Intensity was adjusted according to patient's comfort.~Hot pack was applied on the lumbar region for 10 - 15 minutes.Lumbar Mobilization (CPA) was given on spinous process of L1- L5 vertebrae and L5-S1. For every session given 3 sets of 10 repetitions of each lumbar vertebra was performed.
Study: NCT01168752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0932
Description: Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.~In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met.
Study: NCT01547312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Samples
Description: Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Samples
Description: Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg Grazoprevir
Description: 800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg Grazoprevir
Description: 800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg Grazoprevir
Description: 100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver samples from CNB and FNA
Description: Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
Study: NCT02020772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coordinating primary health care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coordinating primary health care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual primary health care
Study: NCT02806310

Intervention type: OTHER
Intervention: Blood draw
Description: blood sampling for biomarker levels

Intervention type: OTHER
Intervention: Blood draw
Description: blood sampling for biomarker levels
Study: NCT04640090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone app (Wysa)
Description: The commercially available smartphone application, Wysa, offers evidence-based wellness tools such as supportive listening, deep breathing techniques, guided meditation, yoga, and more. Users can communicate via text to a virtual artificial intelligence (AI) chatbot and/or a human well-being coach.
Study: NCT00531024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: 3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
Study: NCT03888196

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax Ginseng Supplementation
Description: 500 mg/day of Panax Ginseng

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: 500 mg/day of Cellulose
Study: NCT01046682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salsalate
Description: Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.
Study: NCT01273402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TF2/IMP288
Description: TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
Study: NCT01109199

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: The full dose of the study intervention is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice flour
Description: The full dose of the placebo comparator is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
Study: NCT03382119

Intervention type: DEVICE
Intervention: Ultrasound with ARFI (acoustic radiation force impulse)
Description: This technology uses sound waves to measure the stiffness of tissue.

Intervention type: DEVICE
Intervention: Ultrasound with ARFI (acoustic radiation force impulse)
Description: This technology uses sound waves to measure the stiffness of tissue.